Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in the study of cancer.
PRIMARY OBJECTIVES:
I. To collect gynecologic tissue and blood from participating Gynecologic Oncology Group (GOG) institutions.
II. To provide a repository for long-term storage of gynecologic tissue and blood that will be used in studies designed to better understand the molecular biology of gynecologic tumors.
III. To make available, through the GOG Tissue Bank, tissue and blood for proposed projects conducted by GOG and non-GOG investigators.
OUTLINE:
Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.
Inclusion Criteria:
Any of the following:
Patients who have had gynecologic tissue removed during surgery to diagnosis, treat, monitor, and/or prevent primary, persistent, or recurrent gynecologic cancer of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, meeting at least one of the following criteria:
Group A: Women who underwent surgery, were diagnosed with a primary gynecologic malignancy of the ovary, cervix, uterine corpus, or vulva, and have primary tumor, normal tissue, and blood available for submission for this protocol
Patients with ovarian cancer including all stages, grades, and common epithelial cell types
Patients with an invasive malignancy of the cervix or uterine corpus including all stages, grades, and common cell types
Patients with squamous cell carcinoma of the vulva
Group B: Women who underwent surgery and were diagnosed with a rare gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, vulva, a gestational trophoblastic tumor, or a tumor arising in endometriosis, and have tumor tissue available for submission for this protocol
Group C: Women who underwent prophylactic oophorectomy and have at least 1 gram of ovarian tissue and blood available for submission for this protocol
Group D: Women who underwent surgery to monitor or treat a persistent or recurrent gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, and have persistent or recurrent tumor, normal tissue, and blood available for submission for this protocol
Concurrent primary cancers are allowed
No benign cystic tumors of the ovary, including cystic epithelial tumors and mature cystic teratomas
Prior cytotoxic chemotherapy allowed
Prior hormonal therapy allowed
Prior radiotherapy allowed
Prior surgery allowed
No more than 6 weeks after prior surgery
Burbank, California 91505, United States
Sacramento, California 95817, United States
Sylmar, California 91342, United States
Aurora, Colorado 80045, United States
Miami, Florida 33136, United States
Baltimore, Maryland 21237, United States
Kessler Air Force Base, Mississippi 39534, United States
Spartanburg, South Carolina 29307, United States
Stevens Point, Wisconsin 54481, United States